Загрузка...
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma. This is p...
Сохранить в:
| Опубликовано в: : | Clin Interv Aging |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210019/ https://ncbi.nlm.nih.gov/pubmed/32440105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S196087 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|